Drug intelligence / Profile preview

inactivated poliovirus vaccine + RotaTeq

Development stage: Unknown
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral, Subcutaneous

Overview

This is a combination of inactivated poliovirus vaccine (IPV) and RotaTeq, which is a live, oral pentavalent rotavirus vaccine. RotaTeq contains five live reassortant rotaviruses derived from human and bovine hosts. The vaccine helps prevent rotavirus gastroenteritis in infants and children caused by rotavirus types G1, G2, G3, G4, and G9. In clinical trials, RotaTeq was administered concomitantly with inactivated poliovirus vaccine (IPV) along with other routine childhood vaccines.

Beyond the preview

Go deeper on inactivated poliovirus vaccine + RotaTeq.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated poliovirus vaccine + RotaTeq.

Explore the full profile